Compare Medpace Holdings Inc (MEDP) vs Manulife Financial Corporation (MFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Manulife Financial Corporation — how do they compare? Medpace Holdings Inc trades at $599.77 (market cap $16.90B), while Manulife Financial Corporation trades at $43.86 (market cap $72.68B). The key difference: Manulife Financial Corporation is far larger — about 4.3× Medpace Holdings Inc's market cap, and Manulife Financial Corporation pays a 3.1% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| MEDP | MFC | |
|---|---|---|
Market Cap | $16.90B | $72.68B |
Sector | Technology | Financials |
52-Week High | $620.59 | $44.77 |
52-Week Low | $393.42 | $30.06 |
Enterprise Value | $16.52B | $67.84B |
Dividend Yield | — | 3.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $600.00, down 0.4% on the day, with a bullish technical signal driven by moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $4.25, and raised full-year guidance. Revenue growth is robust, with 2026 projected at $2.8 billion, though valuation multiples like a P/E of 35.58 and P/B of 38.95 are elevated. Net cash flow is expected to turn positive in 2026, and institutional activity is mixed, with some funds increasing stakes while others trim positions.
Outlook is positive due to earnings momentum and record bookings, but risks include high valuation sensitivity and a shareholder lawsuit investigation. Analyst consensus is a $599.57 price target with a 'Hold' bias, suggesting limited near-term upside from current levels amid growth-priced expectations.
Manulife Financial (MFC) trades at $44.09, down slightly by 0.14% today, with a neutral technical signal and mixed earnings performance. The company reported strong Q2 2026 results with 12% core earnings growth and 21% APE sales growth in Asia, though Q1 results missed expectations. Revenue has grown from $15.3B in 2022 to $53.0B in 2025, with net income margin at 11.7% and ROE of 13.88%. Recent partnerships with Microsoft and Alibaba Cloud highlight strategic AI investments.
MFC presents a balanced outlook with solid fundamentals and growth in Asian markets, supported by a 57% analyst buy rating and $51.50 price target. However, premium valuation (P/E 16.57, P/B 2.18) and mixed technical indicators suggest cautious optimism. Key risks include execution in wealth management, regulatory scrutiny in Hong Kong, and macroeconomic sensitivity. The stock offers steady dividends with recent $0.49 payouts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Manulife Financial Corporation
Manulife provides life insurance and wealth management products and services to individuals and group customers in Canada, the United States, and Asia. Manulife is one of Canada's Big Three Life Insurance companies (the other two are Sun Life and Great West Life). As of Dec. 31, 2021, Manulife reported assets under management or administration of about CAD $1.4 trillion.
Read more on MFC →
